ArticleMolecular neurobiology2025
Cang-Ai Volatile Oil Mitigates Lipopolysaccharide-Induced Depressive-Like Behaviour in Mice by Modulating the Microglial BDNF/CREB Signaling Pathway.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lactobacillus rhamnosus and Saccharomyces boulardii Attenuate LPS-Induced Cognitive and Affective Dysfunction Associated with Hippocampal Neuroinflammatory and Neurochemical Alterations : Probiotics Mitigate LPS-Induced Neuroinflammation and Cognitive Deficits.Neurochemical research · 2026Article
- Cang-Ai Volatile Oil Ameliorates Chronic Unpredictable Mild Stress-Induced Depression-like Symptoms in Rats by Regulating NT/Trk Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- PDCD4: A Double-Edged Sword in Neurological Diseases.Molecular neurobiology · 2026Review
- Anti-Neuroinflammatory Effects of a Representative Low-Molecular-Weight Component Isolated fromMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Depression is a severe mental disorder with evidence suggesting that microglial modulation can play a crucial role in elevating brain-derived neurotrophic factor (BDNF) level in hippocampus. Previous studies highlight that Cang-ai volatile oil (CAVO) exhibits antidepressant effects by inhibiting microglial activation and neuroinflammation while upregulating BDNF expression. This study aimed to investigate CAVO's antidepressant effects through modulating microglial phenotypic polarization and the BDNF/cAMP response element binding protein (CREB) pathway. Results showed that in a Lipopolysaccharide (LPS)-induced depression model, CAVO increased the animals' body weight (BW) and alleviated depressive-like behaviors. CAVO reduced the number of Iba1 and CD16/32 co-localized cells and decreased pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), while increasing IL-4, IL-10, and BDNF levels. In LPS-activated BV2 cells, CAVO reversed the elevated release of pro-inflammatory cytokines and enhanced anti-inflammatory factors, demonstrating a dose-dependent response. Additionally, CAVO treatment significantly elevated CD163 expression while reducing CD86 expression, with the most prominent effects observed at the higher CAVO dose, indicating the potential of CAVO to modulate microglial polarization from an M1 pro-inflammatory state towards an M2 anti-inflammatory phenotype. Western blot analysis confirmed that CAVO elevated BDNF, AKT, and p-CREB while reducing ERK1/2 expression in both mouse and BV2 cells. The findings support the therapeutic potential of CAVO in depression treatment through modulation of inflammatory responses and enhancement of BDNF synthesis via the BDNF/CREB pathway in microglia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.